Search for: "Lisa Larrimore Ouellette" Results 81 - 100 of 122
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
Structural Racism and COVID-19
11 Jun 2020, 2:30 pm by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceOver the past two weeks, the United States&mdash [read post]
Written Description - http://writtendescription.blogspot.com/
Bruno Latour, Mario Biagioli, and the Rhetoric of "Balance" in IP Law (and Climate Change)
14 Jan 2019, 2:40 am by Camilla Alexandra Hrdy
inconclusive empirical evidence regarding the costs and benefits of patents appears on pages 75-87 of Lisa [read post]
Written Description - http://writtendescription.blogspot.com/
Wednesday round-up
21 Jan 2015, 2:46 am by Amy Howe
  Commentary comes from Lisa Larrimore Ouellette at Written Description. [read post]
SCOTUSblog - http://www.scotusblog.com/
How does the CDC’s Advisory Committee on Immunization Practices impact innovation and access to COVID-19 vaccines?
27 Aug 2021, 12:18 pm by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceIn previous blog posts in this series, we have [read post]
Written Description - http://writtendescription.blogspot.com/
How can policymakers overcome the hurdles to scaling up antibody manufacturing?
18 Feb 2021, 10:24 am by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceIn our last post, we introduced some of the clinical [read post]
Written Description - http://writtendescription.blogspot.com/
Nonexcludable Innovations and COVID-19
27 May 2020, 12:00 pm by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
What’s the difference between vaccine approval (BLA) and authorization (EUA)?
3 Jun 2021, 8:56 am by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsRecently, Pfizer and BioNTech and [read post]
Written Description - http://writtendescription.blogspot.com/
What can policymakers learn from the UK’s RECOVERY trial to improve clinical research for COVID-19 and beyond?
3 May 2021, 8:36 am by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceWe have written before about the challenges of [read post]
Written Description - http://writtendescription.blogspot.com/
How does the law impact the use of 3D printing to address COVID-19 production shortages?
27 Apr 2020, 1:27 pm by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowHealth systems worldwide [read post]
Written Description - http://writtendescription.blogspot.com/
Wednesday round-up
22 Mar 2017, 4:42 am by Edith Roberts
” In a Wall Street Journal op-ed, Daniel Hamel and Lisa Larrimore Ouellette maintain that the case [read post]
SCOTUSblog - http://www.scotusblog.com/
How would the proposed American Pandemic Preparedness Plan help address underinvestment in pandemic-related innovation?
27 Sep 2021, 7:26 am by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsHistorically, the United States&rsquo [read post]
Written Description - http://writtendescription.blogspot.com/
Are patents the cause of—or solution to—COVID-19 vaccine innovation problems? (No!)
4 Mar 2021, 10:50 am by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsAre patents the cause of—or [read post]
Written Description - http://writtendescription.blogspot.com/
How can policymakers encourage COVID-19 vaccine trials for children?
18 Dec 2020, 6:37 pm by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsThe past two weeks have been full [read post]
Written Description - http://writtendescription.blogspot.com/
How is the NIH seeking to encourage investment in diagnostic testing for COVID-19?
13 Aug 2020, 8:09 am by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceIn this blog post series, we have written about [read post]
Written Description - http://writtendescription.blogspot.com/
What administrative actions might we expect on COVID-19 in President-elect Biden’s administration?
30 Nov 2020, 7:24 am by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceWhen President-elect Joe Biden is inaugurated in [read post]
Written Description - http://writtendescription.blogspot.com/
How are COVID-19 vaccine manufacturers aiming to encourage trust in the FDA’s approval process?
2 Oct 2020, 7:10 am by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceIn recent weeks, a number of articles have reported [read post]
Written Description - http://writtendescription.blogspot.com/
Multi-Agency Funding for COVID-19 Vaccine Development
19 Aug 2020, 10:58 am by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsModerna, Inc., a Cambridge, MA-based [read post]
Written Description - http://writtendescription.blogspot.com/
How should policymakers use “pull” mechanisms to improve COVID-19 innovation incentives?
30 Jul 2020, 3:39 pm by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
How should policymakers incentivize and regulate convalescent serum therapy for COVID-19?
22 Jul 2020, 12:12 pm by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsOver 120 years ago, a milk wagon [read post]
Written Description - http://writtendescription.blogspot.com/
Why do differences in clinical trial design make it hard to compare COVID-19 vaccines?
30 Jun 2021, 10:31 am by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/